공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

프로테이나제 활성 수용체 2 : 파이프라인 리뷰

Proteinase Activated Receptor 2 - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 379063
페이지 정보 영문 52 Pages
가격
US $ 3,500 ₩ 4,009,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,018,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,027,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


프로테이나제 활성 수용체 2 : 파이프라인 리뷰 Proteinase Activated Receptor 2 - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 52 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

프로테이나제 활성 수용체 2(Proteinase Activated Receptor 2)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보를 최신 뉴스와 발표 등과 함께 전해드립니다.

서론

  • 조사 범위

프로테이나제 활성 수용체 2 개요

치료제 개발

  • 개발중인 제품 : 개발단계별
  • 개발중인 제품 : 치료영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/기관에서 개발중인 제품

치료제 평가

  • 단독치료 제품(Monotherapy Products)/병용요법 제품(Combination Products)별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Hadasit Medical Research Services & Development Ltd
  • Heptares Therapeutics Limited
  • Innovate Biopharmaceuticals, Inc.

약제 프로파일

휴지 상태인 프로젝트

주요 뉴스 및 프레스 릴리스

부록

도표

LSH 16.11.15

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Hadasit Medical Research Services and Development Ltd, H2 2019
  • Pipeline by Innovate Biopharmacueticals Inc, H2 2019
  • Pipeline by Oasis Pharmaceuticals LLC, H2 2019
  • Pipeline by PeptiDream Inc, H2 2019
  • Pipeline by Sosei Heptares, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Protease activated receptor 2 (PAR2) also known as coagulation factor II (thrombin) receptor-like 1 (F2RL1) is a protein encoded by the F2RL1 gene. PARs (protease-activated receptors) are G-protein-coupled receptors for proteases from the circulation, inflammatory cells and epithelial tissues. PAR2 plays an important role in inflammation and pain. Pancreatic (trypsin I and II) and extrapancreatic (trypsin IV) trypsins, mast cell tryptase and coagulation factors VIIa and Xa cleave and activate PAR 2.

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Dermatology, Respiratory, Cardiovascular, Genito Urinary System And Sex Hormones, Metabolic Disorders and Oncology which include indications Atopic Dermatitis (Atopic Eczema), Inflammation, Non-Alcoholic Steatohepatitis (NASH), Celiac Disease, Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Kidney Fibrosis, Obesity, Psoriasis, Pulmonary Fibrosis, Pulmonary Hypertension and Type 2 Diabetes.

The latest report Proteinase Activated Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)
  • The report reviews Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Overview
  • Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Companies Involved in Therapeutics Development
  • Hadasit Medical Research Services and Development Ltd
  • Innovate Biopharmacueticals Inc
  • Oasis Pharmaceuticals LLC
  • PeptiDream Inc
  • Sosei Heptares
  • Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Drug Profiles
  • GB-88 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • larazotide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Antagonize PAR2 for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • P-2pal18S - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Antagonize PAR-1 and PAR-2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PZ-235 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Antagonize PAR2 for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Dormant Products
  • Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Product Development Milestones
  • Featured News & Press Releases
  • Aug 13, 2019: Innovate Biopharmaceuticals announces first patient dosed in the first phase 3 clinical trial for patients with celiac disease
  • Jul 15, 2019: Innovate Biopharmaceuticals announces corporate update and expected date for second quarter earnings release
  • Jun 24, 2019: Innovate Biopharmaceuticals expands its management team with the addition of Ed Sitar as Its Chief Financial Officer
  • Jun 10, 2019: Innovate Biopharmaceuticals announces the start of the first phase 3 clinical trial in Celiac Disease
  • May 20, 2019: Innovate Biopharmaceuticals announces presentation of three posters focusing on the molecular biology and pharmacology of Larazotide at the 2019 Digestive Disease Week Conference in San Diego
  • Apr 29, 2019: Innovate Biopharmaceuticals shows Larazotide is the first drug, with its novel mechanism of action of re-normalizing the intestinal barrier, to demonstrate improvements in validated NASH biomarkers and endpoints in synergy with obeticholic acid, an FXR ag
  • Apr 11, 2019: Innovate Biopharmaceuticals presents oral poster at European Association for the Study of the Liver (EASL) demonstrating positive effect of larazotide on reduced intestinal permeability in a NASH preclinical study
  • Apr 02, 2019: Innovate Biopharmaceuticals to announce first quarter 2019 financial results and to provide operational progress updates on April 29, 2019
  • Mar 19, 2019: Innovate Biopharmaceuticals reports financing to initiate the first phase 3 clinical trial in celiac disease
  • Feb 25, 2019: Innovate Biopharmaceuticals announces acceptance of three abstracts focusing on the molecular biology and pharmacology of Larazotide for the 2019 Digestive Disease Week Conference
  • Dec 17, 2018: Innovate Biopharmaceuticals plans to commence the first ever phase 3 registration trial in celiac disease in 1H 2019 and announce top-line NASH data with drug combinations by EASL 2019
  • Nov 12, 2018: Sanyal Biotechnology and Innovate Biopharmaceuticals present data at AASLD validating a proprietary Leaky Gut assay demonstrating reduced intestinal permeability with Larazotide Acetate treatment in a NASH preclinical study
  • Oct 29, 2018: Innovate Biopharmaceuticals announces positive effect of Larazotide Acetate on reducing intestinal permeability in a NASH preclinical study
  • May 17, 2018: Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.
  • May 09, 2018: Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q